CRISPR Therapeutics files initial beneficial ownership statement for Chief Technical Officer Sivakesava Sakhamuri
CRSP•CRISPR Therapeutics Chief Technical Officer Sivakesava Sakhamuri filed an initial statement of beneficial ownership on Nov. 2, 2026.
1. Ownership filing
Sivakesava Sakhamuri, chief technical officer of CRISPR Therapeutics, filed an initial statement of beneficial ownership on Nov. 2, 2026.
